, Listeria (LM), 32 P or saline on metastases in the portal liver of all five mice in one experiment. One mouse died in the 32 P alone group. Briefly, C57Bl/6 mice were injected with 2 × 10 6 Panc-0 2 tumor cells in the mammary fat pad. All untreated mice develop a primary tumor in the mammary fat pad that extends into the peritoneal membrane and is palpable 3-7 days after tumor cell injection (not shown), and metastases (visible by eye) develop predominantly in the pancreas, portal liver, and in the mesenteric lymph nodes (MLN). All untreated mice develop ascites and die around day 30 as described previously (1). On day 3, mice were injected with 10 7
Supplementary Figure 2:
Listeria alone has no significant effect on advanced pancreatic cancer in Panc-02 and KPC mice. (A) C57Bl/6 mice were injected with 10 5 Panc-02 tumor cells in the mammary fat pad. When tumors reached 8-10 mm (10 days after tumor cell injection), and metastases had spread to all organs, the Panc-02 mice received three cycles of 10 7 CFU of Listeria (LM) alone on four consecutive days, followed by a rest period of three days after each cycle (12 doses total). The mice were euthanized 6 weeks after tumor cell injection. n = 5 mice. The results were averaged. This experiment was performed once. Mann-Whitney p < 0.05 is significant. was generated as described previously (1) . Briefly, C57Bl/6 mice were injected with 2 × 10 6 Panc-02 cells in the mammary fat pad. 3-7 days after injection a relatively small primary tumor is visible in the peritoneal membrane (extended from the mammary fat pad), and metastases are visible predominantly in the pancreas, liver, and mesenteric lymph nodes along the GI (and less frequently in diaphragm, spleen and kidneys; not shown). The picture of this highly aggressive model is shown 28 days after tumor cell injection.
radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci USA. 2013; 110:8668-73. Table 1 7 of CFU Listeria-32P (LM-32P )(Group I) or saline (Group II) every 3 days for 2 weeks. n = 5 mice per group. Pathological examination was performed one month after the last treatment. The samples were graded on a scale of 0-5; 0 = no significant findings, 1 = minimal finding, 2 = mild finding, 3 = moderate finding, 4 = moderate-marked finding, 5 = marked finding, P = present, NP = not present, NSF = no significant finding. There are no notable findings in any of the samples evaluated. There were scattered multifocal minimal inflammation and extramedullary hematopoiesis in the liver, which is normally seen in mice and is not interpreted to be related to the treatment.
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